- A phase I study of ispinesib, a kinesin spindle protein inhibitor, administered weekly for three consecutive weeks of a 28-day cycle in patients with solid tumors. Burris, H.A., Jones, S.F., Williams, D.D., Kathman, S.J., Hodge, J.P., Pandite, L., Ho, P.T., Boerner, S.A., Lorusso, P. Invest. New. Drugs (2011)